



ANSWERS FOR CANCER

Genetron Health to Participate in the 8th BioCentury-BayHelix China Healthcare Summit

November 15, 2021

BEIJING, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced its upcoming participation in the 8th BioCentury-BayHelix China Healthcare Summit to be held November 16-19, 2021.

Genetron Health Chief Financial Officer, Evan Xu, will be a panelist in the "Hands-On Bootcamp: Assessing the Capital Markets Situation in China and the U.S." discussion available on-demand for conference participants. This workshop will address key C-Suite questions and discuss strategies to reduce regulatory risk while meeting investor expectations for global competitiveness.

About Genetron Holdings Limited

Genetron Holdings Limited ("Genetron Health" or the "Company") (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis, and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit <https://ir.genetronhealth.com/>.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as "may," "will," "expect," "anticipate," "target," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

Investor Relations Contact

US:

Hoki Luk

Head of Investor Relations

Email: hluk@genetronhealth.us

Phone: +1 (408) 891-9255

Philip Trip Taylor

Vice President | Gilmartin Group

Email: ir@genetronhealth.com